Introduction
An extremely rare tumor that develops from the pericardial mesothelial cell layers is called primary pericardial malignant mesothelioma. PPM (primary pericardial mesothelioma) is a relatively rare cancer with a very terrible prognosis. Because of its late and non-specific appearance, it provides a diagnostic problem. Although there is no standard treatment for primary pericardial mesothelioma, extensive surgery is the mainstay of treatment for localized illness. The tumor is extremely aggressive and has a poor prognosis, with less than six months of overall survival.
What Is Primary Pericardial Mesothelioma?
The pericardium, the lining that surrounds the heart, is affected by a rare malignancy known as pericardial mesothelioma. The pericardial form of mesothelioma makes up less than 1 percent of all cases. Most victims of this illness are between the ages of 50 and 70. Men experience it more frequently than women do. Later-stage symptoms can resemble those of other heart conditions. Breathlessness, exhaustion, and chest pain are a few of the symptoms. It is difficult to diagnose because these symptoms are identical. Options for treating pericardial disease include chemotherapy and surgery. Certain patients choose not to receive any treatment. Radiation treatment is only sometimes given to patients. There are only about 150 cases of pericardial mesothelioma reported in medical records.
What Are the Symptoms Associated With Pericardial Mesothelioma?
Breathing difficulties, chest pain, and palpitations are common signs of pericardial mesothelioma. Symptoms include thickening of the pericardial tissues and accumulation of fluid around the heart. The majority of people with pericardial mesothelioma initially show no symptoms. This is one of the factors that contribute to a late-stage diagnosis. Pericardial mesothelioma symptoms can sometimes be confused with those of other cardiac disorders. As a result, it is challenging to diagnose. Pericardial mesothelioma may be indicated by the following symptoms:
-
Chest ache.
-
Cough
-
Breathing difficulties, even when at rest (dyspnea).
-
Lethargy and fever.
-
Arrhythmia, irregular heartbeat, or palpitations in the heart.
-
Murmurs.
-
Sweats at night.
-
Breathing difficulties when sleeping flat.
How Is Primary Pericardial Mesothelioma Diagnosed?
Pericardial mesothelioma tumor locations can be determined by imaging studies and physical examinations. The results of a biopsy can establish if they are malignant. Pericardial mesothelioma symptoms and indicators might be found during physical examinations. Imaging tests will be ordered based on the examination findings. Unfortunately, the majority of cases are identified during an autopsy (post-mortem examination). Before a patient passes away, doctors diagnose between 10 and 20 percent of cases. Other diagnostic tests used for primary pericardial mesothelioma are the following.
-
Echocardiography - One of the first diagnostic tests patients will have is an echocardiography. This test involves an ultrasound of the heart, which can identify any fluid buildup. It makes the size, form, and functionality of the heart easier for doctors to see. The non-invasive scan makes use of sound waves.
-
Imaging Tests - Pericardial tumors can be found using imaging techniques like magnetic resonance imaging (MRI) and computed tomography (CT). They are a favored diagnostic method for establishing if a biopsy is required.
-
Biopsy - A biopsy will examine the abnormal growths' composition. Surgeons will excise tissue or fluid from the lump surgically. A pathologist examines the tissue under a microscope to determine the precise subtype of mesothelioma.
What Are the Treatment Options Available for Pericardial Mesothelioma?
Pericardiectomy and tumor excision are the main surgical therapeutic options for pericardial mesothelioma. Treatment options are restricted by the proximity of the cardiac lining to the heart. The most successful treatment for this malignancy is surgery. However, over half of patients are not suitable candidates. Rarely, small, circumscribed tumors may be surgically removed in circumstances of an early diagnosis. Both chemotherapy and palliative care techniques can reduce growth and relieve discomfort. Radiation treatment for this uncommon malignancy is thought to be only marginally helpful. Giving radiation therapy without damaging the heart is dangerous.
-
Removal of a Tumor or Pericardiectomy - A pericardiectomy or tumor excision may be performed on patients who are favorable candidates for surgery. Part or all of the pericardium is removed during a pericardiectomy. Pressure is released, and fluid accumulation is reduced with this operation. Cancer is removed by tumor excision, which keeps the pericardium intact. According to a 2017 analysis, tumor removal results in a longer survival time than pericardiectomy.
-
Chemotherapy - For the majority of pericardial mesothelioma patients, chemotherapy has no benefit. Pemetrexed, as well as Cisplatin and chemotherapy medications, may increase survival. Chemotherapy has been effective in a small number of patients.
-
Palliative Care - The symptoms are mostly caused by an accumulation of fluid in the pericardium. The goal of palliative care is to lessen discomfort and symptoms. Patients' comfort levels and quality of life can both increase with this kind of care. Excess fluid is removed during a pericardiocentesis to reduce pressure and discomfort surrounding the heart. Moreover, painkillers might lessen discomfort and lessen symptoms.
What Is the Prognosis of Primary Pericardial Mesothelioma?
Pericardial mesothelioma has a poor prognosis when compared to other mesothelioma. Within six months of diagnosis, 50 to 60 percent of individuals with pericardial disease pass away. More than 20 percent of patients survive for a year or longer. For pericardial mesothelioma, the 5-year survival rate is 9 percent. Researchers have reported favorable surgical outcomes, which gives some patients hope. Chemotherapy benefits are smaller and less significant.
Conclusion
Primary pericardial mesothelioma is an extremely rare cancer of the pericardial mesothelial lining. Although aggressive surgery is the basis of therapy for localized disease, there is no established therapy for pericardial mesothelioma. The tumor is extremely aggressive and has a poor prognosis, with less than six months of overall survival.
